Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.
Hiroya TaniguchiTakayuki YoshinoKensei YamaguchiKentaro YamazakiAndrew B NixonJosep TaberneroEric Van CutsemKim R RoblingPaolo B AbadaRebecca R HozakRobert W SiegelJeffrey A FillSameera WijayawardanaRichard A WalgrenBrendan GilesAbby JonesKelly R PittsNora DroveKei MuroPublished in: Current medical research and opinion (2021)
In patients with high VEGF-D, ramucirumab demonstrated a greater improvement in OS and PFS vs placebo; however, baseline VEGF-D level was not predictive of ramucirumab OS benefit using VEGF-D assay for IUO. The RAISE intent-to-treat results remain valid.